| Title |
(+)-Grandifloracin, an antiausterity agent, induces autophagic PANC-1 pancreatic cancer cell death
|
|---|---|
| Published in |
Drug Design, Development and Therapy, December 2013
|
| DOI | 10.2147/dddt.s52168 |
| Pubmed ID | |
| Authors |
Jun-ya Ueda, Sirivan Athikomkulchai, Ryuta Miyatake, Ikuo Saiki, Hiroyasu Esumi, Suresh Awale |
| Abstract |
Human pancreatic tumors are known to be highly resistant to nutrient starvation, and this prolongs their survival in the hypovascular (austere) tumor microenvironment. Agents that retard this tolerance to nutrient starvation represent a novel antiausterity strategy in anticancer drug discovery. (+)-Grandifloracin (GF), isolated from Uvaria dac, has shown preferential toxicity to PANC-1 human pancreatic cancer cells under nutrient starvation, with a PC50 value of 14.5 μM. However, the underlying mechanism is not clear. In this study, GF was found to preferentially induce PANC-1 cell death in a nutrient-deprived medium via hyperactivation of autophagy, as evidenced by a dramatic upregulation of microtubule-associated protein 1 light chain 3. No change was observed in expression of the caspase-3 and Bcl-2 apoptosis marker proteins. GF was also found to strongly inhibit the activation of Akt, a key regulator of cancer cell survival and proliferation. Because pancreatic tumors are highly resistant to current therapies that induce apoptosis, the alternative cell death mechanism exhibited by GF provides a novel therapeutic insight into antiausterity drug candidates. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 6 | 18% |
| Student > Master | 6 | 18% |
| Student > Ph. D. Student | 6 | 18% |
| Student > Bachelor | 5 | 15% |
| Professor > Associate Professor | 4 | 12% |
| Other | 2 | 6% |
| Unknown | 5 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 12 | 35% |
| Agricultural and Biological Sciences | 5 | 15% |
| Biochemistry, Genetics and Molecular Biology | 4 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Medicine and Dentistry | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 7 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 January 2014.
All research outputs
#7,047,954
of 25,374,917 outputs
Outputs from Drug Design, Development and Therapy
#452
of 2,268 outputs
Outputs of similar age
#77,051
of 320,962 outputs
Outputs of similar age from Drug Design, Development and Therapy
#6
of 31 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,962 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.